These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Serum thymidine kinase and beta-2 microglobulin in monoclonal gammopathies. Ucci G; Riccardi A; Luoni R; Spriano P; Merlini G; Danova M; Cassano E; Molinari E; Ascari E Tumori; 1987 Oct; 73(5):445-9. PubMed ID: 3318049 [TBL] [Abstract][Full Text] [Related]
30. Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity. Papadaki H; Kyriakou D; Foudoulakis A; Markidou F; Alexandrakis M; Eliopoulos GD Acta Haematol; 1997; 97(4):191-5. PubMed ID: 9158660 [TBL] [Abstract][Full Text] [Related]
31. [Biochemical and immunological findings of multiple myeloma]. Asaoku H Nihon Rinsho; 2007 Dec; 65(12):2256-60. PubMed ID: 18069270 [TBL] [Abstract][Full Text] [Related]
32. Serum thymidine kinase in monoclonal gammopathies. A prospective study. The Cooperative Group for Study and Treatment of Multiple Myeloma. Luoni R; Ucci G; Riccardi A; Gobbi P; Avato FM; Vignale C; Ascari E Cancer; 1992 Mar; 69(6):1368-72. PubMed ID: 1540874 [TBL] [Abstract][Full Text] [Related]
33. Serum thymidine kinase as a prognostic indicator for patients with multiple myeloma: results from the MRC (UK) V trial. Brown RD; Joshua DE; Nelson M; Gibson J; Dunn J; MacLennan IC Br J Haematol; 1993 Jun; 84(2):238-41. PubMed ID: 8398824 [TBL] [Abstract][Full Text] [Related]
34. Clinical and biological significance of serum tumor markers in adult T-cell leukemia. Sadamori N Leuk Lymphoma; 1996 Aug; 22(5-6):415-9. PubMed ID: 8882954 [TBL] [Abstract][Full Text] [Related]
35. [Prognostic Value of Corrected Levels of Serum Calcium and Serum Lactate Dehydrogenase for Newly Diagnosed Multiple Myeloma Patients]. Xie YM; Cui YJ; Li H; Pan XR; Xu YX Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Jun; 27(3):844-849. PubMed ID: 31204942 [TBL] [Abstract][Full Text] [Related]
36. Profiles and prognostic values of serum LDH isoenzymes in patients with haematopoietic malignancies. Bouafia F; Drai J; Bienvenu J; Thieblemont C; Espinouse D; Salles G; Coiffier B Bull Cancer; 2004; 91(7-8):E229-40. PubMed ID: 15381461 [TBL] [Abstract][Full Text] [Related]
37. [The prognostic significance of the beta 2-microglobulin level of the blood serum in multiple myeloma patients]. Lubo-Lesnichenko IF; Bessmel'tsev SS; Abdulkadyrov KM; Blinov MN; Stel'mashenko LV Ter Arkh; 1996; 68(10):28-31. PubMed ID: 9026938 [TBL] [Abstract][Full Text] [Related]
39. The prognostic value of serum beta 2 microglobulin compared with other presentation features in myelomatosis. Cuzick J; Cooper EH; MacLennan IC Br J Cancer; 1985 Jul; 52(1):1-6. PubMed ID: 3893505 [TBL] [Abstract][Full Text] [Related]